Improving imaging guidelines for multiple myeloma

Improving imaging guidelines for multiple myeloma

VJHemOnc

1 year
201 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Guy Pratt, MD, FRCP, FRCPath, of University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, discusses recent guideline changes within multiple myeloma (MM) diagnostics and treatment, focusing on improving imaging modalities, at the 2018 British Society for Haematology (BSH) Annual Scientific Meeting, in Liverpool, UK. Dr Pratt explores utilizing cross-sectional imaging, including the use of whole body MRI, low-dose full body CT scans, and PET scans, recommending these methods for those with suspected MM suggesting a substantial change in practice from the skeletal surveys used previously. Cross-sectional imaging techniques are better able to not only pick up the bone disease that are easily missed in radiographs, but to define the anatomical structure of bone and soft tissue lesions. Moreover, they can be used to define response to treatment, signifying a paradigm shift within MM care.
Up Next Autoplay
JAVELIN Study: How Does This Affect Clinicians?
JAVELIN Study: How Does This Affect Clinicians?
Category: Urology
2 Views
Cancer-News 4 hours
What happened to patients with progression of disease?
What happened to patients with progression of disease?
Category: Urology
3 Views
Cancer-News 5 hours
Phase III JAVELIN Study in Urothelial Cancer @tompowles1
Phase III JAVELIN Study in Urothelial Cancer @tompowles1
Category: Urology
2 Views
Cancer-News 5 hours
Radiotherapy in Localized Prostate Cancer: What is next for treatment?
Radiotherapy in Localized Prostate Cancer: What is next for treatment?
Category: Prostate Cancer
1 Views
Cancer-News 3 days
The Impact of Therapy with External-Beam Radiotherapy
The Impact of Therapy with External-Beam Radiotherapy
Category: Prostate Cancer
1 Views
Cancer-News 3 days
Is there a correlation between the target volume of radiation?
Is there a correlation between the target volume of radiation?
Category: Prostate Cancer
0 Views
Cancer-News 3 days
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with...
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with...
Category: Pancreatic Cancer
0 Views
Cancer-News 3 days
Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial
Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial
Category: Prostate Cancer
2 Views
Cancer-News 3 days
Servier's R&D Efforts in Oncology #ASH #ASH19
Servier's R&D Efforts in Oncology #ASH #ASH19
Category: News
1 Views
ash 3 days
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
Category: News
0 Views
Cancer-News 5 days